BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Czepiel J, Dróżdż M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, Goldman S, Wultańska D, Garlicki A, Biesiada G. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis 2019;38:1211-21. [PMID: 30945014 DOI: 10.1007/s10096-019-03539-6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 29.0] [Reference Citation Analysis]
Number Citing Articles
1 Komatsu T, Inagaki R, Azuma S, Mochida S, Sato Y, Seto Y, Nihonyanagi S, Hoshiyama T, Wada T, Takayama Y, Atsuda K. Evaluation of a carbapenem antimicrobial stewardship program and clinical outcomes in a Japanese hospital. J Infect Chemother 2022:S1341-321X(22)00085-X. [PMID: 35331613 DOI: 10.1016/j.jiac.2022.03.006] [Reference Citation Analysis]
2 Sheehan J, Sadlier C, O'brien B. Bacterial endotoxins and exotoxins in intensive care medicine. BJA Education 2022. [DOI: 10.1016/j.bjae.2022.01.003] [Reference Citation Analysis]
3 Wang S, Zhu D, Sun X. Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection. Microbiol Spectr 2022;:e0026322. [PMID: 35583336 DOI: 10.1128/spectrum.00263-22] [Reference Citation Analysis]
4 Yokoyama Y, Shiota A, Asai N, Koizumi Y, Yamagishi Y, Sakanashi D, Nakamura A, Suematsu H, Ohnishi M, Mikamo H. Risk factors of first recurrence of Clostridioides difficile infection. Anaerobe 2022;:102556. [PMID: 35395406 DOI: 10.1016/j.anaerobe.2022.102556] [Reference Citation Analysis]
5 Itani M, Kaur N, Roychowdhury A, Mellnick VM, Lubner MG, Dasyam AK, Khanna L, Prasad SR, Katabathina VS. Gastrointestinal Manifestations of Immunodeficiency: Imaging Spectrum. Radiographics 2022;:210169. [PMID: 35452341 DOI: 10.1148/rg.210169] [Reference Citation Analysis]
6 Hai Z, Peng Zhen L, Juan M, Fan Y, Jin Rong C, Jing Yao L, Li Xia Z. Extraintestinal Clostridioides difficile infection. IDCases 2020;22:e00921. [PMID: 32923365 DOI: 10.1016/j.idcr.2020.e00921] [Reference Citation Analysis]
7 Karpiński P, Wultańska D, Piotrowski M, Brajerova M, Mikucka A, Pituch H, Krutova M. Motility and the genotype diversity of the flagellin genes fliC and fliD among Clostridioides difficile ribotypes. Anaerobe 2021;73:102476. [PMID: 34780914 DOI: 10.1016/j.anaerobe.2021.102476] [Reference Citation Analysis]
8 Baron SW, Ostrowsky BE, Nori P, Drory DY, Levi MH, Szymczak WA, Rinke ML, Southern WN. Screening of Clostridioides difficile carriers in an urban academic medical center: Understanding implications of disease. Infect Control Hosp Epidemiol 2020;41:149-53. [PMID: 31822302 DOI: 10.1017/ice.2019.309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Guo J, Chen C. Treatment and factors influencing mortality among patients with Clostridium difficile infection. Adv in Digestive Med 2020;7:53-5. [DOI: 10.1002/aid2.13214] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Pipiya SO, Terekhov SS, Mokrushina YA, Knorre VD, Smirnov IV, Gabibov AG. Engineering Artificial Biodiversity of Lantibiotics to Expand Chemical Space of DNA-Encoded Antibiotics. Biochemistry (Mosc) 2020;85:1319-34. [PMID: 33280576 DOI: 10.1134/S0006297920110048] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Aurelia H, Eugen D, Sorin R, Magdalena DI. Clostridium Difficile Infection - Analysis of Risk Factors in Constanta. ARS Medica Tomitana 2020;26:159-62. [DOI: 10.2478/arsm-2020-0032] [Reference Citation Analysis]
12 Rauseo AM, Olsen MA, Reske KA, Dubberke ER. Strategies to prevent adverse outcomes following Clostridioides difficile infection in the elderly. Expert Rev Anti Infect Ther 2020;18:203-17. [PMID: 31976779 DOI: 10.1080/14787210.2020.1717950] [Reference Citation Analysis]
13 Waker E, Ambrozkiewicz F, Kulecka M, Paziewska A, Skubisz K, Cybula P, Targoński Ł, Mikula M, Walewski J, Ostrowski J. High Prevalence of Genetically Related Clostridium Difficile Strains at a Single Hemato-Oncology Ward Over 10 Years. Front Microbiol 2020;11:1618. [PMID: 32793147 DOI: 10.3389/fmicb.2020.01618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Ramos CP, Lopes EO, Diniz AN, Lobato FCF, Vilela EG, Silva ROS. Evaluation of glutamate dehydrogenase (GDH) and toxin A/B rapid tests for Clostridioides (prev. Clostridium) difficile diagnosis in a university hospital in Minas Gerais, Brazil. Braz J Microbiol 2020;51:1139-43. [PMID: 32367261 DOI: 10.1007/s42770-020-00288-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Wang S, Deng W, Li F, Chen YE, Wang PU. Blockade of T helper 17 cell function ameliorates recurrent Clostridioides difficile infection in mice. Acta Biochim Biophys Sin (Shanghai) 2021:gmab107. [PMID: 34379099 DOI: 10.1093/abbs/gmab107] [Reference Citation Analysis]
16 Yang Z, Huang Q, Qin J, Zhang X, Jian Y, Lv H, Liu Q, Li M. Molecular Epidemiology and Risk Factors of Clostridium difficile ST81 Infection in a Teaching Hospital in Eastern China. Front Cell Infect Microbiol 2020;10:578098. [PMID: 33425775 DOI: 10.3389/fcimb.2020.578098] [Reference Citation Analysis]
17 Kim D, Kim Y, Hwang H, Ciufolini MA, Lee J, Lee H, Clovis S, Jung S, Oh S, Son Y, Kwak J. Nitro-Group-Containing Thiopeptide Derivatives as Promising Agents to Target Clostridioides difficile. Pharmaceuticals 2022;15:623. [DOI: 10.3390/ph15050623] [Reference Citation Analysis]
18 Páramo-Zunzunegui J, Ortega-Fernández I, Calvo-Espino P, Diego-Hernández C, Ariza-Ibarra I, Otazu-Canals L, Danés-Grases JE, Menchero-Sánchez A. Severe Clostridium difficile colitis as potential late complication associated with COVID-19. Ann R Coll Surg Engl 2020;102:e176-9. [PMID: 32803988 DOI: 10.1308/rcsann.2020.0166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sullivan MH, Boggiano VL, Smith KL. Management of difficult-to-treat Clostridioides difficile in a patient with chronic osteomyelitis. BMJ Case Rep 2020;13:e233095. [PMID: 32229549 DOI: 10.1136/bcr-2019-233095] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Ramos CP, Diniz AN, Ribeiro MG, de Paula CL, Costa ÉA, Sonne L, Pereira ST, Lopes CEB, Rennó MC, Silva ROS. Enteric Organisms Detected in Feces of Dogs With Bloody Diarrhea: 45 Cases. Top Companion Anim Med 2021;45:100549. [PMID: 34044173 DOI: 10.1016/j.tcam.2021.100549] [Reference Citation Analysis]
21 Kramer P. Mitochondria-Microbiota Interaction in Neurodegeneration. Front Aging Neurosci 2021;13:776936. [PMID: 35002678 DOI: 10.3389/fnagi.2021.776936] [Reference Citation Analysis]
22 Buonsenso D, Graffeo R, Pata D, Valentini P, Palumbo C, Masucci L, Ruggiero A, Attinà G, Onori M, Lancella L, Lucignano B, Giuseppe MD, Bernaschi P, Cursi L. Clostridioides difficile Infection in Children: A 5-Year Multicenter Retrospective Study. Front Pediatr 2022;10:783098. [DOI: 10.3389/fped.2022.783098] [Reference Citation Analysis]
23 Maestri AC, Raboni SM, Morales HMP, Ferrari LF, Tuon FFB, Losso A, Marconi C, Nogueira KDS. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil. Anaerobe 2020;64:102238. [PMID: 32717474 DOI: 10.1016/j.anaerobe.2020.102238] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Brodzicki A, Jaworek-Korjakowska J, Kleczek P, Garland M, Bogyo M. Pre-Trained Deep Convolutional Neural Network for Clostridioides Difficile Bacteria Cytotoxicity Classification Based on Fluorescence Images. Sensors (Basel) 2020;20:E6713. [PMID: 33255305 DOI: 10.3390/s20236713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Ramos CP, Lopes EO, Oliveira Júnior CA, Diniz AN, Lobato FCF, Silva ROS. Immunochromatographic test and ELISA for the detection of glutamate dehydrogenase (GDH) and A/B toxins as an alternative for the diagnosis of Clostridioides (Clostridium) difficile-associated diarrhea in foals and neonatal piglets. Braz J Microbiol 2020;51:1459-62. [PMID: 32363568 DOI: 10.1007/s42770-020-00275-4] [Reference Citation Analysis]
26 AlJindan R, AlEraky DM, Borgio JF, AbdulAzeez S, Abdalhamid B, Mahmoud N, Farhat M. Diagnostic deficiencies of C. difficile infection among patients in a tertiary hospital in Saudi Arabia: A laboratory-based case series. Saudi J Biol Sci 2021;28:4472-7. [PMID: 34354432 DOI: 10.1016/j.sjbs.2021.04.044] [Reference Citation Analysis]
27 Wagner JL, Stover KR, Bell AM, Barber KE. Risk factors for development of initial Clostridioides difficile infection. J Glob Antimicrob Resist 2021;25:18-22. [PMID: 33667706 DOI: 10.1016/j.jgar.2021.02.012] [Reference Citation Analysis]
28 Önning G, Palm R, Linninge C, Larsson N. New Lactiplantibacillus plantarum and Lacticaseibacillus rhamnosus strains: well tolerated and improve infant microbiota. Pediatr Res 2021. [PMID: 34429515 DOI: 10.1038/s41390-021-01678-1] [Reference Citation Analysis]
29 Bhaskara V, Leal MT, Seigner J, Friedrich T, Kreidl E, Gadermaier E, Tesarz M, Rogalli A, Stangl L, Wallwitz J, Hammel K, Rothbauer M, Moll H, Ertl P, Hahn R, Himmler G, Bauer A, Casanova E. Efficient production of recombinant secretory IgA against Clostridium difficile toxins in CHO-K1 cells. J Biotechnol 2021;331:1-13. [PMID: 33689865 DOI: 10.1016/j.jbiotec.2021.02.013] [Reference Citation Analysis]
30 Hotinger JA, Morris ST, May AE. The Case against Antibiotics and for Anti-Virulence Therapeutics. Microorganisms 2021;9:2049. [PMID: 34683370 DOI: 10.3390/microorganisms9102049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Gkartziou F, Giormezis N, Spiliopoulou I, Antimisiaris SG. Nanobiosystems for Antimicrobial Drug-Resistant Infections. Nanomaterials (Basel) 2021;11:1075. [PMID: 33922004 DOI: 10.3390/nano11051075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Li Y, Xia S, Jiang X, Feng C, Gong S, Ma J, Fang Z, Yin J, Yin Y. Gut Microbiota and Diarrhea: An Updated Review. Front Cell Infect Microbiol 2021;11:625210. [PMID: 33937093 DOI: 10.3389/fcimb.2021.625210] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Piotrowski M, Wultańska D, Pituch H. Effect of prebiotics on Bacteroides sp. adhesion and biofilm formation and synbiotic effect on Clostridioides difficile. Future Microbiol 2022. [PMID: 35172601 DOI: 10.2217/fmb-2021-0206] [Reference Citation Analysis]
34 Ranftler C, Nagl D, Sparer A, Röhrich A, Freissmuth M, El-Kasaby A, Nasrollahi Shirazi S, Koban F, Tschegg C, Nizet S. Binding and neutralization of C. difficile toxins A and B by purified clinoptilolite-tuff. PLoS One 2021;16:e0252211. [PMID: 34043688 DOI: 10.1371/journal.pone.0252211] [Reference Citation Analysis]
35 Oliveira Paiva AM, de Jong L, Friggen AH, Smits WK, Corver J. The C-Terminal Domain of Clostridioides difficile TcdC Is Exposed on the Bacterial Cell Surface. J Bacteriol 2020;202:e00771-19. [PMID: 32868401 DOI: 10.1128/JB.00771-19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Abukhalil AD, AbuKhdeir L, Hamed M, Al Shami N, Naseef HA, Aiesh BM, Sabateen A. Characteristics, Risk Factors, and Prevalence of Clostridioides difficile Among Hospitalized Patients in a Tertiary Care Hospital in Palestine. Infect Drug Resist 2021;14:4681-8. [PMID: 34785915 DOI: 10.2147/IDR.S333985] [Reference Citation Analysis]
37 Shaikh DH, Patel H, Munshi R, Sun H, Mehershahi S, Baiomi A, Alemam A, Pirzada U, Nawaz I, Naher K, Hanumanthu S, Nayudu S. Patients with Clostridium difficile infection and prior appendectomy may be prone to worse outcomes. World J Gastrointest Surg 2021; 13(11): 1436-1447 [DOI: 10.4240/wjgs.v13.i11.1436] [Reference Citation Analysis]
38 Kiersnowska ZM, Lemiech-Mirowska E, Semczuk K, Michałkiewicz M, Sierocka A, Marczak M. Level of Knowledge of Medical Staff on the Basis of the Survey in Terms of Risk Management, Associated with Clostridioides difficile Infections. Int J Environ Res Public Health 2021;18:7060. [PMID: 34280996 DOI: 10.3390/ijerph18137060] [Reference Citation Analysis]
39 Palacios Araya D, Palmer KL, Duerkop BA. CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria. PLoS Pathog 2021;17:e1009672. [PMID: 34237097 DOI: 10.1371/journal.ppat.1009672] [Reference Citation Analysis]
40 Sahra S, Jahangir A, De Chavez V. Antimicrobial Stewardship: A Review for Internal Medicine Physicians. Cureus 2021;13:e14385. [PMID: 33976999 DOI: 10.7759/cureus.14385] [Reference Citation Analysis]
41 Kartalidis P, Skoulakis A, Tsilipounidaki K, Florou Z, Petinaki E, Fthenakis GC. Clostridioides difficile as a Dynamic Vehicle for the Dissemination of Antimicrobial-Resistance Determinants: Review and In Silico Analysis. Microorganisms 2021;9:1383. [PMID: 34202117 DOI: 10.3390/microorganisms9071383] [Reference Citation Analysis]
42 Intra J, Carcione D, Sarto C, Brambilla P. A significant decreased in the frequency of Clostridioides difficile infection at the Italian Hospital of Desio over the last decade. Anaerobe 2021;70:102376. [PMID: 33901657 DOI: 10.1016/j.anaerobe.2021.102376] [Reference Citation Analysis]
43 Heinzinger LR, Johnson A, Wurster JI, Nilson R, Penumutchu S, Belenky P. Oxygen and Metabolism: Digesting Determinants of Antibiotic Susceptibility in the Gut. iScience 2020;23:101875. [PMID: 33354661 DOI: 10.1016/j.isci.2020.101875] [Reference Citation Analysis]
44 Rzucidło-Hymczak A, Hymczak H, Kędziora A, Kapelak B, Drwiła R, Plicner D. Prognostic role of perioperative acid-base disturbances on the risk of Clostridioides difficile infection in patients undergoing cardiac surgery. PLoS One 2021;16:e0248512. [PMID: 33730090 DOI: 10.1371/journal.pone.0248512] [Reference Citation Analysis]
45 Karczewski D, Müllner M, Perka C, Müller M. Clostridium difficile septic arthritis and periprosthetic joint infection in a patient with acute lymphoblastic leukaemia, T-/B-lymphocytopenia and hypogammaglobulinemia - a case report and review of the literature. Access Microbiol 2021;3:000233. [PMID: 34151183 DOI: 10.1099/acmi.0.000233] [Reference Citation Analysis]
46 Silva ROS, Ribeiro MG, de Paula CL, Pires IH, Oliveira Junior CA, Diniz AN, de Araújo Nunes TA, Lobato FCF. Isolation of Clostridium perfringens and Clostridioides difficile in diarrheic and nondiarrheic cats. Anaerobe 2020;62:102164. [PMID: 32151948 DOI: 10.1016/j.anaerobe.2020.102164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ojha SC, Phanchana M, Harnvoravongchai P, Chankhamhaengdecha S, Singhakaew S, Ounjai P, Janvilisri T. Teicoplanin Suppresses Vegetative Clostridioides difficile and Spore Outgrowth. Antibiotics (Basel) 2021;10:984. [PMID: 34439034 DOI: 10.3390/antibiotics10080984] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Efiana NA, Dizdarević A, Huck CW, Bernkop-Schnürch A. Improved Intestinal Mucus Permeation of Vancomycin via Incorporation Into Nanocarrier Containing Papain-Palmitate. J Pharm Sci 2019;108:3329-39. [PMID: 31136766 DOI: 10.1016/j.xphs.2019.05.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Lyle CA, Caputo FJ. Abdominal aortic endograft infection with Clostridium difficile. Vascular 2021;:17085381211053689. [PMID: 34839756 DOI: 10.1177/17085381211053689] [Reference Citation Analysis]
50 Panchavati S, Zelin NS, Garikipati A, Pellegrini E, Iqbal Z, Barnes G, Hoffman J, Calvert J, Mao Q, Das R. A comparative analysis of machine learning approaches to predict C. difficile infection in hospitalized patients. American Journal of Infection Control 2022. [DOI: 10.1016/j.ajic.2021.11.012] [Reference Citation Analysis]
51 Jeng HS, Yan TR. Lactiplantibacillus plantarum E51 protects against Clostridioides difficile-induced damages on Caco-2 intestinal barrier functions. Arch Microbiol 2022;204:290. [PMID: 35503482 DOI: 10.1007/s00203-022-02837-6] [Reference Citation Analysis]
52 Teixeira H, Freitas A, Sarmento A, Nossa P, Gonçalves H, Pina MF. Spatial Patterns in Hospital-Acquired Infections in Portugal (2014-2017). Int J Environ Res Public Health 2021;18:4703. [PMID: 33925064 DOI: 10.3390/ijerph18094703] [Reference Citation Analysis]
53 Todorov SD, Kang HJ, Ivanova IV, Holzapfel WH. Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis. Front Bioeng Biotechnol 2020;8:581778. [PMID: 33042979 DOI: 10.3389/fbioe.2020.581778] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Han DK, Oh J, Lee J, Cho YG, Park JS, Choi JS, Kim DS, Kwon J. Paper-based multiplex analytical device for simultaneous detection of Clostridioides difficile toxins and glutamate dehydrogenase. Biosens Bioelectron 2021;176:112894. [PMID: 33358286 DOI: 10.1016/j.bios.2020.112894] [Reference Citation Analysis]
55 Ye J, Chu AJ, Lin L, Chan ST, Harper R, Xiao M, Artsimovitch I, Zuo Z, Ma C, Yang X. Benzyl and benzoyl benzoic acid inhibitors of bacterial RNA polymerase-sigma factor interaction. Eur J Med Chem 2020;208:112671. [PMID: 32920341 DOI: 10.1016/j.ejmech.2020.112671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Yuan Y, Wang X, Xu X, Liu Y, Li C, Yang M, Yang Y, Ma Z. Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders. ACS Infect Dis 2020;6:820-31. [DOI: 10.1021/acsinfecdis.9b00374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
57 Aguilar-zamora E, Weimer BC, Torres RC, Gómez-delgado A, Ortiz-olvera N, Aparicio-ozores G, Barbero-becerra VJ, Torres J, Camorlinga-ponce M. Molecular Epidemiology and Antimicrobial Resistance of Clostridioides difficile in Hospitalized Patients From Mexico. Front Microbiol 2022;12:787451. [DOI: 10.3389/fmicb.2021.787451] [Reference Citation Analysis]
58 Czepiel J, Krutova M, Mizrahi A, Khanafer N, Enoch DA, Patyi M, Deptuła A, Agodi A, Nuvials X, Pituch H, Wójcik-Bugajska M, Filipczak-Bryniarska I, Brzozowski B, Krzanowski M, Konturek K, Fedewicz M, Michalak M, Monpierre L, Vanhems P, Gouliouris T, Jurczyszyn A, Goldman-Mazur S, Wultańska D, Kuijper EJ, Skupień J, Biesiada G, Garlicki A. Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study. Antibiotics (Basel) 2021;10:299. [PMID: 33805755 DOI: 10.3390/antibiotics10030299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Abruzzo A, Giordani B, Miti A, Vitali B, Zuccheri G, Cerchiara T, Luppi B, Bigucci F. Mucoadhesive and mucopenetrating chitosan nanoparticles for glycopeptide antibiotic administration. Int J Pharm 2021;606:120874. [PMID: 34252521 DOI: 10.1016/j.ijpharm.2021.120874] [Reference Citation Analysis]
60 Pörner D, Von Vietinghoff S, Nattermann J, Strassburg CP, Lutz P. Advances in the pharmacological management of bacterial peritonitis. Expert Opin Pharmacother 2021;22:1567-78. [PMID: 33878993 DOI: 10.1080/14656566.2021.1915288] [Reference Citation Analysis]
61 Kumar A, Ellermann M, Sperandio V. Taming the Beast: Interplay between Gut Small Molecules and Enteric Pathogens. Infect Immun 2019;87:e00131-19. [PMID: 31262983 DOI: 10.1128/IAI.00131-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
62 Speri E, Janardhanan J, Masitas C, Schroeder VA, Lastochkin E, Wolter WR, Fisher JF, Mobashery S, Chang M. Discovery of a Potent Picolinamide Antibacterial Active against Clostridioides difficile. ACS Infect Dis 2020;6:2362-8. [PMID: 32786277 DOI: 10.1021/acsinfecdis.0c00479] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
63 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
64 Hughes J, Aston C, Kelly ML, Griffin R. Towards Development of a Non-Toxigenic Clostridioides difficile Oral Spore Vaccine against Toxigenic C. difficile. Pharmaceutics 2022;14:1086. [DOI: 10.3390/pharmaceutics14051086] [Reference Citation Analysis]
65 Ferreira EO, Penna B, Yates EA. Should We Be Worried About Clostridioides difficile During the SARS-CoV2 Pandemic? Front Microbiol 2020;11:581343. [PMID: 33133048 DOI: 10.3389/fmicb.2020.581343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Ramos CP, Diniz AN, Leite SM, Lobato FCF, Pereira ST, Rennó MC, de Oliveira Ferreira E, Silva ROS. Evaluation of an immunochromatographic test for the detection of glutamate dehydrogenase for the diagnosis of Clostridioides (Clostridium) difficile infection in dogs. Braz J Microbiol 2021;52:2555-8. [PMID: 34562233 DOI: 10.1007/s42770-021-00615-y] [Reference Citation Analysis]
67 Gilbert J, Leslie J, Putler R, Weiner S, Standke A, Penkevich A, Keidan M, Young VB, Rao K. Anti-toxin antibody is not associated with recurrent Clostridium difficile infection. Anaerobe 2021;67:102299. [PMID: 33227427 DOI: 10.1016/j.anaerobe.2020.102299] [Reference Citation Analysis]
68 Itani M, Menias CO, Mellnick VM, El Zakhem A, Elsayes K, Katabathina V, Revzin MV. Imaging of abdominal and pelvic infections in the cancer patient. Abdom Radiol (NY) 2021;46:2920-41. [PMID: 33386914 DOI: 10.1007/s00261-020-02896-7] [Reference Citation Analysis]
69 Xavier JB, Monk JM, Poudel S, Norsigian CJ, Sastry AV, Liao C, Bento J, Suchard MA, Arrieta-ortiz ML, Peterson EJ, Baliga NS, Stoeger T, Ruffin F, Richardson RA, Gao CA, Horvath TD, Haag AM, Wu Q, Savidge T, Yeaman MR. Mathematical models to study the biology of pathogens and the infectious diseases they cause. iScience 2022;25:104079. [DOI: 10.1016/j.isci.2022.104079] [Reference Citation Analysis]
70 Wendt S, Ranft D, Rodloff AC, Lippmann N, Lübbert C. Switching From Ceftriaxone to Cefotaxime Significantly Contributes to Reducing the Burden of Clostridioides difficile infections. Open Forum Infect Dis 2020;7:ofaa312. [PMID: 33005693 DOI: 10.1093/ofid/ofaa312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Papić N, Jelovčić F, Karlović M, Marić LS, Vince A. Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection. Eur J Clin Microbiol Infect Dis 2020;39:569-74. [DOI: 10.1007/s10096-019-03759-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
72 Vasilescu I, Chifiriuc M, Pircalabioru GG, Filip R, Bolocan A, Lazăr V, Diţu L, Bleotu C. Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults. Front Microbiol 2022;12:651081. [DOI: 10.3389/fmicb.2021.651081] [Reference Citation Analysis]
73 Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol 2021;14:17562848211018654. [PMID: 34104214 DOI: 10.1177/17562848211018654] [Reference Citation Analysis]
74 Meza-Torres J, Auria E, Dupuy B, Tremblay YDN. Wolf in Sheep's Clothing: Clostridioides difficile Biofilm as a Reservoir for Recurrent Infections. Microorganisms 2021;9:1922. [PMID: 34576818 DOI: 10.3390/microorganisms9091922] [Reference Citation Analysis]
75 Strasser C, Spindelboeck W, Kashofer K, Oswald J, Haid B. Low-dose antibiotic prophylaxis has no significant impact on the stability of the intestinal microbiome in children with urogenital tract malformations under 1 year of age. J Pediatr Urol 2020;16:456.e1-7. [PMID: 32665196 DOI: 10.1016/j.jpurol.2020.05.165] [Reference Citation Analysis]
76 Shiode J, Fujii M, Nasu J, Itoh M, Ishiyama S, Fujiwara A, Yoshioka M. Correlation between hospital-onset and community-onset Clostridioides difficile infection incidence: ward-level analysis following hospital relocation. American Journal of Infection Control 2022. [DOI: 10.1016/j.ajic.2022.02.004] [Reference Citation Analysis]
77 Amlerova J, Šroubek J, Angelucci F, Hort J. Evidences for a Role of Gut Microbiota in Pathogenesis and Management of Epilepsy. Int J Mol Sci 2021;22:5576. [PMID: 34070389 DOI: 10.3390/ijms22115576] [Reference Citation Analysis]
78 Brugaletta G, De Cesare A, Zampiga M, Laghi L, Oliveri C, Zhu C, Manfreda G, Syed B, Valenzuela L, Sirri F. Effects of Alternative Administration Programs of a Synbiotic Supplement on Broiler Performance, Foot Pad Dermatitis, Caecal Microbiota, and Blood Metabolites. Animals (Basel) 2020;10:E522. [PMID: 32245036 DOI: 10.3390/ani10030522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Moreira RS, Filho VB, Calomeno NA, Wagner G, Miletti LC. EpiBuilder: A Tool for Assembling, Searching, and Classifying B-Cell Epitopes. Bioinform Biol Insights 2022;16:117793222210952. [DOI: 10.1177/11779322221095221] [Reference Citation Analysis]
80 Hernández M, Saura N, García S, Velamazán R, Abad D, Hijos G, Alfaro E, Cañamares P, Laredo V, Lorente S. Recurrent Clostridium difficile infection treated with bezlotoxumab in a liver transplant patient. Gastroenterol Hepatol 2021;44:720-1. [PMID: 33199130 DOI: 10.1016/j.gastrohep.2020.09.015] [Reference Citation Analysis]
81 Liu Y, Alnababtah K, Cook S, Yu Y. Healthcare providers' perception of faecal microbiota transplantation with clostridium difficile infection and inflammatory bowel disease: a quantitative systematic review. Therap Adv Gastroenterol 2021;14:17562848211042679. [PMID: 34567271 DOI: 10.1177/17562848211042679] [Reference Citation Analysis]
82 Lee HY, Hsiao HL, Chia CY, Cheng CW, Tsai TC, Deng ST, Chen CL, Chiu CH. Risk factors and outcomes of Clostridium difficile infection in hospitalized patients. Biomed J 2019;42:99-106. [PMID: 31130254 DOI: 10.1016/j.bj.2018.12.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Kulecka M, Waker E, Ambrozkiewicz F, Paziewska A, Skubisz K, Cybula P, Targoński Ł, Mikula M, Walewski J, Ostrowski J. Higher genome variability within metabolism genes associates with recurrent Clostridium difficile infection. BMC Microbiol 2021;21:36. [PMID: 33509087 DOI: 10.1186/s12866-021-02090-9] [Reference Citation Analysis]
84 Rosignoli C, Petruzzellis G, Radici V, Facchin G, Girgenti M, Stella R, Isola M, Battista M, Sperotto A, Geromin A, Cerno M, Arzese A, Deias P, Tascini C, Fanin R, Patriarca F. Risk Factors and Outcome of C. difficile Infection after Hematopoietic Stem Cell Transplantation. J Clin Med 2020;9:E3673. [PMID: 33207616 DOI: 10.3390/jcm9113673] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Charoenngam N, Ponvilawan B, Thongpiya J, Yingchoncharoen P, Chaikijurajai T, Chaisidhivej N, Apovian CM, Ungprasert P. Body mass index and risk of clostridioides difficile infection: a systematic review and meta-analysis. Infection 2022. [PMID: 34985688 DOI: 10.1007/s15010-021-01749-9] [Reference Citation Analysis]
86 Cebrián R, Macia-Valero A, Jati AP, Kuipers OP. Design and Expression of Specific Hybrid Lantibiotics Active Against Pathogenic Clostridium spp. Front Microbiol 2019;10:2154. [PMID: 31616392 DOI: 10.3389/fmicb.2019.02154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
87 Romyasamit C, Thatrimontrichai A, Aroonkesorn A, Chanket W, Ingviya N, Saengsuwan P, Singkhamanan K. Enterococcus faecalis Isolated From Infant Feces Inhibits Toxigenic Clostridioides (Clostridium) difficile. Front Pediatr 2020;8:572633. [PMID: 33102409 DOI: 10.3389/fped.2020.572633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Phanchana M, Phetruen T, Harnvoravongchai P, Raksat P, Ounjai P, Chankhamhaengdecha S, Janvilisri T. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile. Sci Rep 2020;10:6497. [PMID: 32300130 DOI: 10.1038/s41598-020-63199-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
89 Yu X, Jiang W, Huang X, Lin J, Ye H, Liu B. rRNA Analysis Based on Long-Read High-Throughput Sequencing Reveals a More Accurate Diagnostic for the Bacterial Infection of Ascites. Biomed Res Int 2021;2021:6287280. [PMID: 34869767 DOI: 10.1155/2021/6287280] [Reference Citation Analysis]
90 León Y, Faherty CS. Bacteriophages against enteropathogens: rediscovery and refinement of novel antimicrobial therapeutics. Curr Opin Infect Dis 2021;34:491-9. [PMID: 34524200 DOI: 10.1097/QCO.0000000000000772] [Reference Citation Analysis]
91 Narita K, Asano K, Naito K, Ohashi H, Sasaki M, Morimoto Y, Igarashi T, Nakane A. 222-nm UVC inactivates a wide spectrum of microbial pathogens. J Hosp Infect 2020:S0195-6701(20)30129-8. [PMID: 32243946 DOI: 10.1016/j.jhin.2020.03.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
92 Monma T, Iwamoto J, Honda A, Ueda H, Kakizaki F, Yara S, Miyazaki T, Ikegami T. Evaluation of the Risk of Clostridium difficile Infection Using a Serum Bile Acid Profile. Metabolites 2022;12:331. [DOI: 10.3390/metabo12040331] [Reference Citation Analysis]
93 Łukawska A, Mulak A. Impact of Primary and Secondary Bile Acids on Clostridioides difficile Infection. Polish Journal of Microbiology 2022;0. [DOI: 10.33073/pjm-2022-007] [Reference Citation Analysis]
94 Martínez-Meléndez A, Morfin-Otero R, Villarreal-Treviño L, Baines SD, Camacho-Ortíz A, Garza-González E. Analysis of biofilm production and expression of adhesion structures of circulating Clostridioides difficile strains from Mexico. Enferm Infecc Microbiol Clin (Engl Ed) 2021:S0213-005X(21)00042-2. [PMID: 33714640 DOI: 10.1016/j.eimc.2021.01.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
95 Qi H, Sun Q, Ma Y, Wu P, Wang J. Advantages of Lateral Flow Assays Based on Fluorescent Submicrospheres and Quantum Dots for Clostridium difficile Toxin B Detection. Toxins (Basel) 2020;12:E722. [PMID: 33227925 DOI: 10.3390/toxins12110722] [Reference Citation Analysis]
96 Shaffer SR, Nugent Z, Walkty A, Yu BN, Lix LM, Targownik LE, Bernstein CN, Singh H. Time trends and predictors of laboratory-confirmed recurrent and severe Clostridioides difficile infections in Manitoba: a population-based study. CMAJ Open 2020;8:E737-46. [PMID: 33199507 DOI: 10.9778/cmajo.20190191] [Reference Citation Analysis]
97 Piotrowski M, Wultańska D, Pituch H. The prebiotic effect of human milk oligosaccharides 3'- and 6'-sialyllactose on adhesion and biofilm formation by Clostridioides difficile - pilot study. Microbes Infect 2021;:104929. [PMID: 34958948 DOI: 10.1016/j.micinf.2021.104929] [Reference Citation Analysis]
98 Fettucciari K, Fruganti A, Marchegiani A, Brancorsini S, Marconi P, Bassotti G. Proinflammatory Cytokines: Possible Accomplices for the Systemic Effects of Clostridioides difficile Toxin B. J Inflamm Res 2021;14:57-62. [PMID: 33469335 DOI: 10.2147/JIR.S287096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Czepiel J, Biesiada G, Pitera E, Wołkow PP, Michalak M, Garlicki A. Decreased Expression of the High Mobility Group Box 1 (HMGB1) Gene in Peripheral Blood in Patients with Mild or Moderate Clostridioides difficile Infection. Microorganisms 2020;8:E1217. [PMID: 32796569 DOI: 10.3390/microorganisms8081217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Abdrabou AMM, Bischoff M, Mellmann A, von Müller L, Margardt L, Gärtner BC, Berger FK, Haase G, Häfner H, Hoffmann R, Simon V, Stappmanns H, Hischebeth GT, Büchler C, Rößler S, Hochauf-stange K, Pfeffer K, Mackenzie C, Kunz C, Alsalameh R, Dziobaka J, le Chapot VS, Sanabria E, Hogardt M, Komp J, Imirzalioglu C, Schmiedel J, Pararas M, Sommer F, Groß U, Bohne W, Kekulé AS, Dagwadordsch U, Löffler B, Rödel J, Walker SV, Tobys D, Weikert-asbeck S, Hauswaldt S, Kaasch AJ, Zautner AE, Joß N, Siegel E, Kehr K, Schaumburg F, Schoeler S, Hamprecht A, Hellkamp J, Hagemann JB, Kubis J, Hering S, Warnke P. Implementation of a Clostridioides difficile sentinel surveillance system in Germany: First insights for 2019–2021. Anaerobe 2022. [DOI: 10.1016/j.anaerobe.2022.102548] [Reference Citation Analysis]
101 Šamadan L, Jeličić M, Vince A, Papić N. Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent Clostridioides difficile Infection. Antibiotics (Basel) 2021;10:780. [PMID: 34198964 DOI: 10.3390/antibiotics10070780] [Reference Citation Analysis]
102 Li M, Behrenbruch C, Wong A, An V. Megacolon following ileostomy reversal due to Clostridium difficile. ANZ J Surg 2020;90:1769-70. [PMID: 32618080 DOI: 10.1111/ans.16124] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Weiss A, Lopez CA, Beavers WN, Rodriguez J, Skaar EP. Clostridioides difficile strain-dependent and strain-independent adaptations to a microaerobic environment. Microb Genom 2021;7. [PMID: 34908523 DOI: 10.1099/mgen.0.000738] [Reference Citation Analysis]
104 Klezovich-Bénard M, Bouchand F, Rouveix E, Goossens PL, Davido B. Management and characteristics of patients suffering from Clostridiodes difficile infection in primary care. Eur J Gen Pract 2021;27:320-5. [PMID: 34755587 DOI: 10.1080/13814788.2021.1998447] [Reference Citation Analysis]
105 Vedala K, Sobash P, Shah P, Kamoga GR. Does Fecal Microbiota Transplant Have a Role in Treating Recurrent Clostridioides difficile Infection in Rural Hospitals? Front Public Health 2021;9:670941. [PMID: 34178927 DOI: 10.3389/fpubh.2021.670941] [Reference Citation Analysis]
106 Martínez-meléndez A, Cruz-lópez F, Morfin-otero R, Maldonado-garza HJ, Garza-gonzález E. An Update on Clostridioides difficile Binary Toxin. Toxins 2022;14:305. [DOI: 10.3390/toxins14050305] [Reference Citation Analysis]
107 Sahra S, Abureesh M, Amarnath S, Alkhayyat M, Badran R, Jahangir A, Gumaste V. Clostridioides difficile infection in liver cirrhosis patients: A population-based study in United States. World J Hepatol 2021; 13(8): 926-938 [PMID: 34552699 DOI: 10.4254/wjh.v13.i8.926] [Reference Citation Analysis]
108 Lin Z, Iqbal Z, Ortiz JF, Khan SA, Jahan N. Fecal Microbiota Transplantation in Recurrent Clostridium Difficile Infection: Is it Superior to Other Conventional Methods? Cureus 2020;12:e9653. [PMID: 32923252 DOI: 10.7759/cureus.9653] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Oksi J, Anttila VJ, Mattila E. Treatment of Clostridioides (Clostridium) difficile infection. Ann Med 2020;52:12-20. [PMID: 31801387 DOI: 10.1080/07853890.2019.1701703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
110 Siwczak F, Loffet E, Kaminska M, Koceva H, Mahe MM, Mosig AS. Intestinal Stem Cell-on-Chip to Study Human Host-Microbiota Interaction. Front Immunol 2021;12:798552. [PMID: 34938299 DOI: 10.3389/fimmu.2021.798552] [Reference Citation Analysis]
111 Bakalchuk MM; National Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic Institute”. FECAL MICROBIOTES TRANSPLANTATION TECHNOLOGIES: MEDICAL, BIOTECHNOLOGICAL AND REGULATORY ASPECTS. Biotechnol acta 2021;14:46-56. [DOI: 10.15407/biotech14.01.46] [Reference Citation Analysis]
112 Alammari KM, Thabit AK. Characteristics of patients infected with Clostridioides difficile at a Saudi Tertiary Academic Medical Center and assessment of antibiotic duration. Gut Pathog 2021;13:10. [PMID: 33593421 DOI: 10.1186/s13099-021-00405-9] [Reference Citation Analysis]
113 Colomb-Cotinat M, Assouvie L, Durand J, Daniau C, Leon L, Maugat S, Soing-Altrach S, Gateau C, Couturier J, Arnaud I, Astagneau P, Berger-Carbonne A, Barbut F. Epidemiology of Clostridioides difficile infections, France, 2010 to 2017. Euro Surveill 2019;24. [PMID: 31481147 DOI: 10.2807/1560-7917.ES.2019.24.35.1800638] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
114 Pitcher NP, Harjani JR, Zhao Y, Jin J, Knight DR, Li L, Putsathit P, Riley TV, Carter GP, Baell JB. Development of 1,2,4-Oxadiazole Antimicrobial Agents to Treat Enteric Pathogens within the Gastrointestinal Tract. ACS Omega. [DOI: 10.1021/acsomega.1c06294] [Reference Citation Analysis]
115 Tydeman F, Craine N, Kavanagh K, Adams H, Reynolds R, McClure V, Hughes H, Hickman M, Robertson C. Incidence of Clostridioides difficile infection (CDI) related to antibiotic prescribing by GP surgeries in Wales. J Antimicrob Chemother 2021:dkab204. [PMID: 34151964 DOI: 10.1093/jac/dkab204] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Taylor W, Camilleri E, Craft DL, Korza G, Granados MR, Peterson J, Szczpaniak R, Weller SK, Moeller R, Douki T, Mok WWK, Setlow P. DNA Damage Kills Bacterial Spores and Cells Exposed to 222-Nanometer UV Radiation. Appl Environ Microbiol 2020;86:e03039-19. [PMID: 32033948 DOI: 10.1128/AEM.03039-19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
117 Gruber P, Hoppe V, Grochowska E, Paleczny J, Junka A, Smolina I, Kurzynowski T. Material Extrusion-Based Additive Manufacturing of Poly(Lactic Acid) Antibacterial Filaments-A Case Study of Antimicrobial Properties. Polymers (Basel) 2021;13:4337. [PMID: 34960888 DOI: 10.3390/polym13244337] [Reference Citation Analysis]
118 Bassotti G, Fruganti A, Maconi G, Marconi P, Fettucciari K. Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease May be Favoured by the Effects of Proinflammatory Cytokines on the Enteroglial Network. J Inflamm Res 2021;14:7443-53. [PMID: 35002278 DOI: 10.2147/JIR.S328628] [Reference Citation Analysis]
119 Abukhalil AD, Abukhdeir L, Hamed M, Al Shami N, Naseef HA, Aiesh BM, Sabateen A. Characteristics, Risk Factors, and Prevalence of Clostridioides difficile Among Hospitalized Patients in a Tertiary Care Hospital in Palestine. IDR 2021;Volume 14:4681-8. [DOI: 10.2147/idr.s333985] [Reference Citation Analysis]
120 Montravers P, Eckmann C. Cotrimoxazole and clindamycin in skin and soft tissue infections. Curr Opin Infect Dis 2021;34:63-71. [PMID: 33278179 DOI: 10.1097/QCO.0000000000000698] [Reference Citation Analysis]
121 Sharma SK, Yip C, Simon MP, Phan J, Abel-Santos E, Firestine SM. Studies on the Importance of the 7α-, and 12α- hydroxyl groups of N-Aryl-3α,7α,12α-trihydroxy-5β-cholan-24-amides on their Antigermination Activity Against a Hypervirulent Strain of Clostridioides (Clostridium) difficile. Bioorg Med Chem 2021;52:116503. [PMID: 34837818 DOI: 10.1016/j.bmc.2021.116503] [Reference Citation Analysis]
122 Whittle E, Yonkus JA, Jeraldo P, Alva-Ruiz R, Nelson H, Kendrick ML, Grys TE, Patel R, Truty MJ, Chia N. Optimizing Nanopore Sequencing for Rapid Detection of Microbial Species and Antimicrobial Resistance in Patients at Risk of Surgical Site Infections. mSphere 2022;:e0096421. [PMID: 35171692 DOI: 10.1128/msphere.00964-21] [Reference Citation Analysis]
123 Deng M, Wu X, Duan X, Xu J, Yang X, Sheng X, Lou P, Shao C, Lv C, Yu Z. Lactobacillus paracasei L9 improves colitis by expanding butyrate-producing bacteria that inhibit the IL-6/STAT3 signaling pathway. Food Funct 2021;12:10700-13. [PMID: 34605504 DOI: 10.1039/d1fo02077c] [Reference Citation Analysis]
124 Rasooly R, Howard AC, Balaban N, Hernlem B, Apostolidis E. The Effect of Tannin-Rich Witch Hazel on Growth of Probiotic Lactobacillus plantarum. Antibiotics 2022;11:395. [DOI: 10.3390/antibiotics11030395] [Reference Citation Analysis]